Login
$RNA
$6.52 +$0.09 (1.4%) After hours

$RNA 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome —

02 Nov 2026 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 Atrium Therapeutics 2 November 2026 RNA L I S T E D www.atriumtherapeutics.com NASDAQ 1

27 Oct 2026 8-K: Other Events

Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2026, by and among Atrium Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement...

13 Aug 2026 8-K: Results of Operations and Financial Condition

— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in

14 Jul 2026 8-K: Other Events

— ATR 1072 is the company’s first precision cardiology program to enter the clinic --

14 May 2026 8-K: Results of Operations and Financial Condition

SAN DIEGO, May 14, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the...

27 Feb 2026 8-K: Entry into a Material Definitive Agreement; Changes in Control of Registrant +1 more

Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Such omitted information has been noted in this document with a pla...

26 Feb 2026 8-K: Regulation FD Disclosure

This information statement is being furnished to existing stockholders of Avidity Biosciences, Inc. (“Avidity”) in connection with the pro rata distribution (the “Distribution”) by Avidity of all the issued and outstanding shares of comm...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support